The com­pa­ny be­hind As­traZeneca's Covid-19 vac­cine just went pub­lic, weeks af­ter com­plet­ing mon­ster Se­ries B, as Were­wolf al­so makes the Nas­daq leap

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The com­pa­ny be­hind the tech­nol­o­gy for As­traZeneca’s Covid-19 vac­cine is prepped and ready to hit Nas­daq.

British biotech Vac­citech priced its IPO late Thurs­day night, pulling in a $110.5 mil­lion raise and will de­but at the mid­point of their range at $17. It’s a quick pub­lic leap for the com­pa­ny, hav­ing com­plet­ed a Se­ries B just last month — though that crossover proved to be huge at $168 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER